Financial Comparison
AbbVie Inc. vs Merck & Co., Inc.
Click a ticker to view the full analysis.
In short
Merck & Co., Inc. is the more profitable of the two, keeping 28.1% of revenue as net profit against 6.9% for AbbVie Inc. Merck & Co., Inc. trades at the higher trailing P/E (113.0× vs 77.0× for AbbVie Inc.), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for AbbVie Inc. and 1 for Merck & Co., Inc.
Based on filings for periods ending 30 Jun 2026 (ABBV) and 30 Jun 2026 (MRK) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABBV shown solid · MRK shown dashed. Not financial advice.
| Metric | ABBV | MRK |
|---|---|---|
| Price | $272.42 | $142.38 |
| Market Cap | $481.4B | $351.3B |
| P/E (TTM) | 77.0x | 113.0x |
| P/B | — | 8.4x |
| Beta | 0.23 | 0.22 |
| Div Yield | 2.46% | 2.34% |
| Revenue (TTM) | $61.2B | $65.0B |
| Net Income | $4.2B | $18.3B |
| Gross Margin | — | — |
| Risk Flags | 2 flags | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.